Related Experiment Video

Updated: Aug 14, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Low molecular weight heparins in cardiovascular medicine

F De Lorenzo1, O Dotsenko, V V Kakkar

  • 1Unit of General Medicine and Preventative Cardiovascular Medicine, Chelsea and Westminster Hospital, NHS Trust, London, UK. dlorenzo@tri-london.ac.uk

Minerva Cardioangiologica
|December 8, 2005
PubMed

Insights

Low molecular weight heparins are safe and effective anticoagulants for preventing and treating various thrombotic events in cardiovascular diseases. Recent trials confirm their role in managing deep vein thrombosis, pulmonary embolism, and myocardial infarction.

Area of Science:

  • Cardiology
  • Hematology
  • Vascular Medicine

Background:

  • Cardiovascular diseases (CVDs) are a leading cause of death globally, with atherosclerosis-driven thrombosis being a key factor.
  • The increasing prevalence of CVDs, especially in developing nations, highlights the need for effective antithrombotic strategies.

Purpose of the Study:

  • To review recent clinical evidence on the use of low molecular weight heparins (LMWHs) in the prevention and treatment of cardiovascular diseases.
  • To summarize the efficacy and safety of LMWHs in various thrombotic conditions.

Main Methods:

  • Systematic review of recent clinical trials and studies.
  • Analysis of data on LMWH use in arterial and venous thrombosis, and thromboembolic event prevention.

Main Results:

  • LMWHs are established as safe and effective anticoagulants for deep vein thrombosis, pulmonary embolism, unstable angina, and non-ST-segment elevation myocardial infarction.
  • LMWHs demonstrate significant roles in preventing thromboembolic events in chronic diseases and post-surgery.
  • Emerging evidence suggests potential benefits of LMWHs in ST-segment elevation myocardial infarction, heart failure, and percutaneous coronary interventions.

Conclusions:

  • Low molecular weight heparins are crucial in managing and preventing a wide spectrum of thrombotic events associated with cardiovascular diseases.
  • Continued research and clinical trials are exploring expanded applications for LMWHs in complex cardiovascular conditions.

More Related Videos

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings06:39

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings

Published on: June 13, 2025

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...